Article

Difference In What Medicare Spends On Cancer Care May Not Affect Survival Rates

Although Medicare spending for patients with advance cancers varies regionally, a new study suggests that those differences are not related to survival rates.

The study, published Tuesday in the Journal of the National Cancer Institute, examined Medicare spending on patients with advanced lung, colorectal, pancreatic, breast, and prostate cancers. Cancer care costs account for approximately 10 percent of Medicare payments and effective treatments to “prolong survival in this population are limited,” the researchers noted.

Read the full story: http://bit.ly/YYtolQ

Source: Kaiser Health News

Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
Galen Shearn-Nance, BS
Dr Johnie Rose
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Cathy Eng, MD, FACP, FASCO
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo